Etrolizumab is a humanized monoclonal antibody targeting integrin receptors containing the ITGB7 (β7) subunit (namely α4β7 and αEβ7).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. Peptide sequence matches indicate that US7528236 is the covering patent [4
]. The likely candidate antibody clone is that designated hu504.32R.
Etrolizumab has a slightly different mechanism of action compared to the already approved ulcerative colitis biologic vedolizumab
(Entyvio®), which targets only α4β7 integrin.